A 'path to cures' or more unfunded FDA, NIH mandates?
This article was originally published in SRA
Executive Summary
After several months of discussion and a series of hearings, roundtables and "listening sessions" with various stakeholders and experts, US lawmakers are on the verge of revealing bipartisan legislation aimed at finding new and successful ways to accelerate the country's discovery, development and delivery processes for new medicines.